Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities

Antiviral Research

Volumn 121, Issue , 2015, Pages 47-58

  Gish, Robert G ^a   Given, Bruce D ^b   Lai, Ching Lung ^c   Locarnini, Stephen A ^d   Lau, Johnson Y N ^e   Lewis, David L ^b   Schluep, Thomas ^b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b Arrowhead Research Corporation   (United States)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^e HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

Author keywords

Antiviral therapy; Functional cure; Hepatitis B virus; Phases of infection; Trained immunity; Virological cure

Indexed keywords

ALPHA INTERFERON; HEPATITIS B(E) ANTIGEN; HOST FACTOR; PEGINTERFERON ALPHA; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTIVIRUS AGENT;

ARTICLE; CHRONIC HEPATITIS B; FOLLOW UP; HEPATITIS B VIRUS; HISTORY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; LIVER CELL; LIVER CELL DAMAGE; MOLECULAR BIOLOGY; PRIORITY JOURNAL; VIRAL CLEARANCE; VIREMIA; VIROLOGY; DISEASE COURSE; HEPATITIS B, CHRONIC; HOST PATHOGEN INTERACTION; PATHOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DISEASE PROGRESSION; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HOST-PATHOGEN INTERACTIONS; HUMANS; TREATMENT OUTCOME;

EID: 84940195264     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2015.06.008     Document Type: Review

References (135)

1. S.F. Baqai, J. Proudfoot, D.H. Yi, M. Mangahas, and R.G. Gish High rate of core promoter and precore mutations in patients with chronic hepatitis B Hepatol. Int. 9 2015 209 217
2. L. Belloni, L. Allweiss, F. Guerrieri, N. Pediconi, T. Volz, T. Pollicino, J. Petersen, G. Raimondo, M. Dandri, and M. Levrero IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenic regulation of the nuclear cccDNA minichromosome J. Clin. Invest. 122 2012 529 537
3. L. Belloni, L. Li, G.A. Palumbo, S.R. Chirapu, L. Calvo, M.G. Finn, U. Lopatin, A. Zlotnick, and M. Levrero HAPs hepatitis B virus (HBV) capsid inhibitors prevent HBc interaction with the viral minichromosome and selected host cell genes to inhibits transcription and affect cccDNA stability Dig. Liver Dis. 46 2014 e9
4. A. Bertoletti, A.T. Tan, and A.J. Gehring HBV-specific adaptive immunity Viruses 1 2009 91 103
5. T.M. Block, R. Gish, H. Guo, A. Mehta, A. Cuconati, W.T. London, and J.-T. Guo Chronic hepatitis B: what should be the goal for new therapies Antiviral Res. 98 2013 27 34
6. K. Bloom, A. Ely, C. Mussolino, T. Cathomen, and P. Arbuthnot Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases Mol. Ther. 21 2013 1889 1897
7. C.T. Bock, S. Schwinn, C.H. Schroder, I. Velhagen, and H. Zentgraf Localization of hepatitis B virus core protein and viral DNA at the nuclear membrane Virus Genes 12 1996 53 63
8. C. Boni, D. Laccabue, P. Lampertico, T. Giuberti, M. Vigano, S. Schivazappa, A. Alfieri, M. Pesci, G.B. Gaeta, G. Brancaccio, M. Colombo, G. Missale, and C. Ferrari Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues Gastroenterology 143 963-973 2012 e969
9. F. Bortolotti, M. Guido, S. Bartolacci, P. Cadrobbi, C. Crivellaro, F. Noventa, G. Morsica, M. Moriondo, and A. Gatta Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study Hepatology 43 2006 556 562
10. D.L. Brassard, M.J. Grace, and R.W. Bordens Interferon-alpha as an immunotherapeutic protein J. Leukoc. Biol. 71 2002 565 581
11. D.L. Brassard, M.J. Grace, and R.W. Bordens Interferon-alpha as an immunotherapeutic protein J. Leukoc. Biol. 71 2002 565 581
12. E.H.C.J. Buster, and H.L.A. Janssen Antiviral treatment for chronic hepatitis B virus infection - immune modulation or viral suppression Neth. J. Med. 64 2006 175 185
13. D. Cai, C. Mills, W. Yu, R. Yan, C.E. Aldrich, J.R. Saputelli, W.S. Mason, X. Xu, J.T. Guo, T.M. Block, A. Cuconati, and H. Guo Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation Antimicrob. Agents Chemother. 56 2012 4277 4288
14. H.L. Chan, C.K. Chan, A.J. Hui, S. Chan, F. Poordad, T.T. Chang, P. Mathurin, J.F. Flaherty, L. Lin, A. Corsa, A. Gaggar, G.M. Subramanian, J.G. McHutchison, G. Lau, S. Lee, and E.J. Gane Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA Gastroenterology 146 2014 1240 1248
15. T.T. Chang, C.L. Lai, S. Kew Yoon, S.S. Lee, H.S. Coelho, F.J. Carrilho, F. Poordad, W. Halota, Y. Horsmans, N. Tsai, H. Zhang, D.J. Tenney, R. Tamez, and U. Iloeje Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B Hepatology 51 2010 422 430
16. R.-N. Chien, and Y.-F. Liaw Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success Best Pract. Res. Clin. Gastroenterol. 22 2008 1081 1092
17. R.N. Chien, Y.F. Liaw, and M. Atkins Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group Hepatology 30 1999 770 774
18. W. Chotiyaputta, and A.S. Lok Hepatitis B virus variants Nat. Rev. Gastroenterol. Hepatol. 6 2009 453 462
19. C.J. Chu, E.B. Keeffe, S.H. Han, R.P. Perrillo, A.D. Min, C. Soldevila-Pico, W. Carey, R.S. Brown Jr.; V.A. Luketic, N. Terrault, A.S. Lok Group, U.S.H.E.S. Prevalence of HBV precore/core promoter variants in the United States Hepatology 38 2003 619 628
20. A.M. Cooper, and S.A. Khader IL-12p40: an inherently agonistic cytokine Trends Immunol. 28 2007 33 38
21. T.J. Cradick, K. Keck, S. Bradshaw, A.C. Jamieson, and A.P. McCaffrey Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs Mol. Ther. 18 2010 947 954
22. D.S. Dane, C.H. Cameron, and M. Briggs Virus-like particles in serum of patients with Australia-antigen-associated hepatitis Lancet 1 1970 695 698
23. G.L. Davis, J.H. Hoofnagle, and J.G. Waggoner Spontaneous reactivation of chronic hepatitis B virus infection Gastroenterology 86 1984 230 235
24. W.E.t. Delaney, R. Edwards, D. Colledge, T. Shaw, P. Furman, G. Painter, and S. Locarnini Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro Antimicrob. Agents Chemother. 46 2002 3057 3060
25. S.D. Der, A. Zhou, B.R.G. Williams, and R.G. Silverman Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays Proc. Natl. Acad. Sci. U.S.A. 95 1998 15623 15628
26. K. Deres, C.H. Schroder, A. Paessens, S. Goldmann, H.J. Hacker, O. Weber, T. Kramer, U. Niewohner, U. Pleiss, J. Stoltefuss, E. Graef, D. Koletzki, R.N. Masantschek, A. Reimann, R. Jaeger, R. Gross, B. Beckermann, K.H. Schlemmer, D. Haebich, and H. Rubsamen-Waigmann Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids Science 299 2003 893 896
27. C. Dunn, D. Peppa, P. Khanna, G. Nebbia, M. Jones, N. Brendish, R.M. Lascar, D. Brown, R.J. Gilson, R.J. Tedder, G.M. Dusheiko, M. Jacobs, P. Klenerman, and M.K. Maini Temporal analysis of early immune responses in patients with acute hepatitis B virus infection Gastroenterology 137 2009 1289 1300
28. G.M. Dusheiko, B.A. Brink, J.D. Conradie, T. Marimuthu, and R. Sher Regional prevalence of hepatitis B, delta, and human immunodeficiency virus infection in southern Africa: a large population survey Am. J. Epidemiol. 129 1989 138 145
29. EASL EASL clinical practice guidelines: management of chronic hepatitis B J. Hepatol. 50 2009 227 242
30. A. Erhardt, D. Blondin, K. Hauck, A. Sagir, T. Kohnle, T. Heintges, and D. Haussinger Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D Gut 54 2005 1009 1013
31. G. Fattovich, M. Rugge, L. Brollo, P. Pontisso, F. Noventa, M. Guido, A. Alberti, and G. Realdi Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B Hepatology 6 1986 167 172
32. M.A. Feitelson, H.M. Reis, N.L. Tufan, B. Sun, J. Pan, and Z. Lian Putative roles of hepatitis B x antigen in the pathogenesis of chronic liver disease Cancer Lett. 286 2009 69 79
33. C. Ferrari HBV and the immune response Liver Int. 35 Suppl. 1 2015 121 128
34. H.J. Flink, D. Sprengers, B.E. Hansen, M. van Zonneveld, R.A. de Man, S.W. Schalm, and H.L.A. Janssen Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during peg-interferon alpha-2b therapy Gut 54 2005 1604 1609
35. C.T. Frenette, and R.G. Gish To "Be" or not to "Be": that is the question Am. J. Gastroenterol. 104 2009 1948 1952
36. A. Gaggar, C. Coeshott, D. Apelian, T. Rodell, B.R. Armstrong, G. Shen, G.M. Subramanian, and J.G. McHutchison Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study Vaccine 32 2014 4925 4931
37. D. Ganem Assembly of hepadnaviral virions and subviral particles Curr. Top. Microbiol. Immunol. 168 1991 61 83
38. D. Ganem, and A.M. Prince Hepatitis B virus infection-natural history and clinical consequences N. Engl. J. Med. 350 2004 1118 1129
39. A.L. Goldstein, and A.L. Goldstein From lab to bedside: emerging clinical applications of thymosin alpha 1 Expert Opin. Biol. Ther. 9 2009 593 608
40. S. Goodbourn, L. Didcock, and R.E. Randall Interferons: cell signaling, immune modulation, antiviral responses, and virus countermeasures J. Gen. Virol. 81 2000 2341 2364
41. Y.H. Guo, Y.N. Li, J.R. Zhao, J. Zhang, and Z. Yan HBc binds to the CpG islands of HBV cccDNA and promotes an epigenetic permissive state Epigenetics 6 2011 720 726
42. I.D. Gust Epidemiology of hepatitis B infection in the Western Pacific and South East Asia Gut 38 Suppl. 2 1996 S18 23
43. S.J. Hadziyannis, N.C. Tassopoulos, E.J. Heathcote, T.T. Chang, G. Kitis, M. Rizzetto, P. Marcellin, S.G. Lim, Z. Goodman, M.S. Wulfsohn, S. Xiong, J. Fry, C.L. Brosgart, and G. Adefovir Dipivoxil 438 Study Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B N. Engl. J. Med. 348 2003 800 807
44. S.J. Hadziyannis, and D. Vassilopoulos Hepatitis B e antigen-negative chronic hepatitis B Hepatology 34 2001 617 624
45. Heathcote Treatment of HBe antigen-positive chronic hepatitis b Semin. Liver Dis. 2003 23
46. M. Hong, E. Sandalova, D. Low, A.J. Gehring, S. Fieni, B. Amadei, S. Urbani, Y.S. Chong, E. Guccione, and A. Bertoletti Trained immunity in newborn infants of HBV-infected mothers Nat. Commun. 6 2015 6588
47. J. Hoofnagle Reactivation of hepatitis B Hepatology 49 2009 S156 165
48. J.H. Hoofnagle, G.M. Dusheiko, L.B. Seeff, E.A. Jones, J.G. Waggoner, and Z.B. Bales Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis Ann. Intern. Med. 94 1981 744 748
49. Y.S. Hsu, R.N. Chien, C.T. Yeh, I.S. Sheen, H.Y. Chiou, C.M. Chu, and Y.F. Liaw Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B Hepatology 35 2002 1522 1527
50. M.S. Iannacone, Guidotti Giovanni, and G. Luca Pathogenetic and antiviral immune responses against hepatitis b virus Future Virol. 1 2006 189 196
51. S.-M.R. Jafri, and A.S.-F. Lok Antiviral therapy for chronic hepatitis B Clin. Liver Dis. 2010 425 438
52. H.L. Janssen, M. van Zonneveld, H. Senturk, S. Zeuzem, U.S. Akarca, Y. Cakaloglu, C. Simon, T.M. So, G. Gerkan, R.A. de Man, H.G. Niesters, P. Zondervan, B. Hansen, S.W. Schalm, H.B.V.S. Group, and R. Rotterdam Foundation for Liver Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial Lancet 365 2005 123 129
53. Y.F. Jiang, Z.H. Ma, P.W. Zhao, Y. Pan, Y.Y. Liu, J.Y. Feng, and J.Q. Niu Effect of thymosin-alpha(1) on T-helper 1 cell and T-helper 2 cell cytokine synthesis in patients with hepatitis B virus e antigen-positive chronic hepatitis B J. Int. Med. Res. 38 2010 2053 2062
54. S.A. Jones, and J. Hu Hepatitis B virus reverse transcriptase: diverse functions as classical and emerging targets for antiviral intervention Emerg. Microbes Infect. 2 2013 e56
55. J.H. Kao Hepatitis B viral genotypes: clinical relevance and molecular characteristics J. Gastroenterol. Hepatol. 17 2002 643 650
56. M.C. Kew Progress towards the comprehensive control of hepatitis B in Africa: a view from South Africa Gut 38 1996 S31 36
57. C.F. Kiire The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a view from tropical and subtropical Africa Gut 38 1996 S5 12
58. Y. Kondo, M. Ninomiya, E. Kakazu, O. Kimura, and T. Shimosegawa Hepatitis B surface antigen could contribute to the immunopathogenesis of hepatitis B virus infection ISRN Gastroenterol. 2013 2013 935295
59. A.D. Kosinska, E. Zhang, L. Johrden, J. Liu, P.L. Seiz, X. Zhang, Z. Ma, T. Kemper, M. Fiedler, D. Glebe, O. Wildner, U. Dittmer, M. Lu, and M. Roggendorf Combination of DNA prime-adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model PLoS Pathog. 9 2013 e1003391
60. K.V. Kowdley, C.C. Wang, S. Welch, H. Roberts, and C.L. Brosgart Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin Hepatology 56 2012 422 433
61. A. Kuo, and R. Gish Chronic hepatitis B infection Clin. Liver Dis. 16 2012 347 369
62. C.L. Lai, E. Gane, Y.F. Liaw, C.W. Hsu, S. Thongsawat, Y. Wang, Y. Chen, E.J. Heathcote, J. Rasenack, N. Bzowej, N.V. Naoumov, A.M. Di Bisceglie, S. Zeuzem, Y.M. Moon, Z. Goodman, G. Chao, B.F. Constance, N.A. Brown, and G. Globe Study Telbivudine versus lamivudine in patients with chronic hepatitis B N. Engl. J. Med. 357 2007 2576 2588
63. C.L. Lai, D. Shouval, A.S. Lok, T.T. Chang, H. Cheinquer, Z. Goodman, D. DeHertogh, R. Wilber, R.C. Zink, A. Cross, R. Colonno, L. Fernandes, and B.E.A.S. Group Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B N. Engl. J. Med. 354 2006 1011 1020
64. C.-L. Lai, D. Wong, P. Ip, M. Kopaniszen, W.-K. Seto, J. Fung, F.-Y. Huang, B.P. Lee, G. Cullaro, C.H. Wu, C. Cheng, C.H.J. Yuen, V. Ngai, and M.-F. Yuen Profound reduction in HBV covalently closed circular DNA with long-term nucleosid/tide analogue therapy Hepatology 60 2014 1090A
65. P. Lampertico The royal wedding in chronic hepatitis B: the haves and the have-nots for the combination of pegylated interferon and nucleos(t)ide therapy Hepatology 61 2015 1459 1461
66. R.E. Lanford, B. Guerra, D. Chavez, L. Giavedoni, V.L. Hodara, K.M. Brasky, A. Fosdick, C.R. Frey, J. Zheng, G. Wolfgang, R.L. Halcomb, and D.B. Tumas GS-9620, an oral agonist of Toll-like receptor-7 induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees Gastroenterology 144 2013 1508 1517 1517 e1501-1510
67. G.K. Lau, T. Piratvisuth, K.X. Luo, P. Marcellin, S. Thongsawat, G. Cooksley, E. Gane, M.W. Fried, W.C. Chow, S.W. Paik, W.Y. Chang, T. Berg, R. Flisiak, P. McCloud, N. Pluck, and H.-P.C.H.B.S.G. Peginterferon Alfa-2a Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B N. Engl. J. Med. 352 2005 2682 2695
68. D. Lavanchy Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures J. Viral Hepat. 11 2004 97 107
69. E.B. Lewellyn, and D.D. Loeb The arginine clusters of the carboxy-terminal domain of the core protein of hepatitis B virus make pleiotropic contributions to genome replication J. Virol. 85 2011 1298 1309
70. Y.F. Liaw, N. Leung, J.H. Kao, T. Piratvisuth, E. Gane, K.H. Han, R. Guan, G.K. Lau, and S. Locarnini Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update Hepatol. Int. 2 2008 263 283
71. J. Liu, H.I. Yang, M.H. Lee, S.N. Lu, C.L. Jen, R. Batrla-Utermann, L.Y. Wang, S.L. You, C.K. Hsiao, P.J. Chen, C.J. Chen Group, R.E.V.E.A.L.H.S. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma Gut 63 2014 1648 1657
72. A.S. Lok, C.L. Lai, P.C. Wu, E.K. Leung, and T.S. Lam Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection Gastroenterology 92 1987 1839 1843
73. A.S. Lok, and B.J. McMahon Chronic hepatitis B: update 2009 Hepatology 50 2009 661 662
74. J. Lucifora, K. Esser, and U. Protzer Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes Antiviral Res. 97 2013 195 197
75. J. Lucifora, Y. Xia, F. Reisinger, K. Zhang, D. Stadler, X. Cheng, M.F. Sprinzl, H. Koppensteiner, Z. Makowska, T. Volz, C. Remouchamps, W.M. Chou, W.E. Thasler, N. Huser, D. Durantel, T.J. Liang, C. Munk, M.H. Heim, J.L. Browning, E. Dejardin, M. Dandri, M. Schindler, M. Heikenwalder, and U. Protzer Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA Science 343 2014 1221 1228
76. S. Lunemann, D.F. Malone, J. Hengst, K. Port, J. Grabowski, K. Deterding, A. Markova, B. Bremer, V. Schlaphoff, M. Cornberg, M.P. Manns, J.K. Sandberg, H.G. Ljunggren, N.K. Bjorkstrom, and H. Wedemeyer Compromised function of natural killer cells in acute and chronic viral hepatitis J. Infect. Dis. 209 2014 1362 1373
77. M.A. Mahtab, M. Bazinet, and A. Viaillant REP 9 AC: a potent HBsAg release inhibitor that elicits durable immunological control of chronic HBV infection Hepatology 54 2011 478A
78. P. Marcellin, G.K. Lau, F. Bonino, P. Farci, S. Hadziyannis, R. Jin, Z.M. Lu, T. Piratvisuth, G. Germanidis, C. Yurdaydin, M. Diago, S. Gurel, M.Y. Lai, P. Button, N. Pluck, and H.-N.C.H.B.S.G. Peginterferon Alfa-2a Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B N. Engl. J. Med. 351 2004 1206 1217
79. P. Marcellin, E.J. Heathcote, M. Buti, E. Gane, R.A. de Man, Z. Krastev, G. Germanidis, S.S. Lee, R. Flisiak, K. Kaita, M. Manns, I. Kotzev, K. Tchernev, P. Buggisch, F. Weilert, O.O. Kurdas, M.L. Shiffman, H. Trinh, M.K. Washington, J. Sorbel, J. Anderson, A. Snow-Lampart, E. Mondou, J. Quinn, and F. Rousseau Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B N. Engl. J. Med. 359 2008 2442 2455
80. P. Marcellin, T. Piratvisuth, M. Brunetto, F. Bonino, G.K.K. Lau, P. Farci, C. Yurdaydin, J. Wu, and M. Popescu Virological and biochemical response in patients with HBeAg-negative chronic hepatitis b treated with peginterferon alfa-2a (40KD) with or without lamivudine: results of 4-year follow-up J. Hepatol. 48 2008 S46
81. P. Martin, C. Dubois, E. Jacquier, S. Dion, M. Mancini-Bourgine, O. Godon, R. Kratzer, K. Lelu-Santolaria, A. Evlachev, J.F. Meritet, Y. Schlesinger, D. Villeval, J.M. Strub, A. Van Dorsselaer, J.B. Marchand, M. Geist, R. Brandely, A. Findeli, H. Boukhebza, T. Menguy, N. Silvestre, M.L. Michel, and G. Inchauspe TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice Gut 2014
82. B.J. McMahon Epidemiology and natural history of hepatitis B Semin. Liver Dis. 25 Suppl. 1 2005 3 8
83. B.J. McMahon, W.L. Alward, D.B. Hall, W.L. Heyward, T.R. Bender, D.P. Francis, and J.E. Maynard Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state J. Infect. Dis. 151 1985 599 603
84. B.J. McMahon, P. Holck, L. Bulkow, and M. Snowball Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus Ann. Intern. Med. 135 2001 759 768
85. G.M. McQuillan, P.J. Coleman, D. Kruszon-Moran, L.A. Moyer, S.B. Lambert, and H.S. Margolis Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994 Am. J. Public Health 89 1999 14 18
86. S. Menne, D.B. Tumas, K.H. Liu, L. Thampi, D. AlDeghaither, B.H. Baldwin, C.A. Bellezza, P.J. Cote, J. Zheng, R. Halcomb, A. Fosdick, S.P. Fletcher, S. Daffis, L. Li, P. Yue, G.H. Wolfgang, and B.C. Tennant Sustained efficacy and seroconversion with the toll-like receptor 7 agonist GS-9620 in the woodchuck model of chronic hepatitis B J. Hepatol. 2015
87. M. Nassal Hepatitis B viruses: reverse transcription a different way Virus Res. 134 2008 235 249
88. K.B. Nguyen, W.T. Watford, R. Salomon, S.R. Hofmann, G.C. Pien, A. Morinobu, M. Gadina, J.J. O'Shea, and C.A. Biron Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection Science 297 2002 2063 2066
89. S. Nkongolo, Y. Ni, F.A. Lempp, C. Kaufman, T. Lindner, K. Esser-Nobis, V. Lohmann, W. Mier, S. Mehrle, and S. Urban Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor J. Hepatol. 60 2014 723 731
90. J.J. Ott, G.A. Stevens, J. Groeger, and S.T. Wiersma Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity Vaccine 30 2012 2212 2219
91. R.-J. Pei, X.-W. Chen, and M.-J. Lu Control of hepatitis B virus replication by interferons and Toll-like receptor signaling pathways World J. Gastroenterol. 20 2014 11618 11629
92. R.P. Perrillo, R. Gish, and Y.T. Falck-Ytter American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy Gastroenterology 148 221-244 2015 e223
93. R.P. Perrillo, C.L. Lai, Y.F. Liaw, J.L. Dienstag, E.R. Schiff, S.W. Schalm, E.J. Heathcote, N.A. Brown, M. Atkins, M. Woessner, and S.D. Gardner Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B Hepatology 36 2002 186 194
94. J. Petersen, M. Dandri, W. Mier, M. Lutgehetmann, T. Volz, F. von Weizsacker, U. Haberkorn, L. Fischer, J.M. Pollok, B. Erbes, S. Seitz, and S. Urban Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein Nat. Biotechnol. 26 2008 335 341
95. G.C. Pien, K.B. Nguyen, L. Malmgaard, A.R. Satoskar, and C.A. Biron A unique mechanism for innate cytokine promotion of T cell responses to viral infections J. Immunol. 169 2002 5827 5837
96. T. Pollicino, and G. Raimondo Occult hepatitis B infection J. Hepatol. 61 2014 688 689
97. T. Pollicino, and C. Saitta Occult hepatitis B virus and hepatocellular carcinoma World J. Gastroenterol. 20 2014 5951 5961
98. G. Raimondo, G. Caccamo, R. Filomia, and T. Pollicino Occult HBV infection Semin. Immunopathol. 35 2013 39 52
99. J.S. Rawlings, K.M. Rosler, and D.A. Harrison The JAK/STAT signaling pathway J. Cell Sci. 117 2004 1281 1283
100. K.R. Reddy, K.L. Beavers, S.P. Hammond, J.K. Lim, and Y.T. Falck-Ytter American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy Gastroenterology 148 2015 215 219
101. S.M. Riordan, N. Skinner, J. Kurtovic, S. Locarnini, and K. Visvanathan Reduced expression of toll-like receptor 2 on peripheral monocytes in patients with chronic hepatitis B Clin. Vaccine Immunol. 13 2006 972 974
102. M.D. Robek, S.F. Wieland, and F.V. Chisari Inhibition of hepatitis B virus replication by interferon requires proteasome activity J. Virol. 76 2002 3570 3574
103. W.S. Robinson, and L.I. Lutwick The virus of hepatitis, type B (first of two parts) N. Engl. J. Med. 295 1976 1168 1175
104. C. Saitta, G. Tripodi, A. Barbera, A. Bertuccio, A. Smedile, A. Ciancio, G. Raffa, A. Sangiovanni, G. Navarra, G. Raimondo, and T. Pollicino Hepatitis B virus (HBV) DNA integration in patients with occult HBV infection and hepatocellular carcinoma Liver Int. 2015
105. T. Santantonio, M. Mazzola, T. Iacovazzi, A. Miglietta, A. Guastadisegni, and G. Pastore Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine J. Hepatol. 32 2000 300 306
106. P.P. Scaglioni, M. Melegari, and J.R. Wands Posttranscriptional regulation of hepatitis B virus replication by the precore protein J. Virol. 71 1997 345 353
107. A. Seetharam, R. Perrillo, and R. Gish Immunosuppression in patients with chronic hepatitis B Curr. Hepatol. Rep. 13 2014 235 244
108. D.A. Shafritz, D. Shouval, H.I. Sherman, S.J. Hadziyannis, and M.C. Kew Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens N. Engl. J. Med. 305 1981 1067 1073
109. D. Shouval, C.L. Lai, T.T. Chang, H. Cheinquer, P. Martin, G. Carosi, S. Han, S. Kaymakoglu, R. Tamez, J. Yang, D. Tenney, and H. Brett-Smith Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy J. Hepatol. 50 2009 289 295
110. B.R. Speed, M. Dimitrakakis, K. Thoma, and I.D. Gust Control of HBV and HDV infection in an isolated Pacific Island: 1. Pattern of infection J. Med. Virol. 29 1989 13 19
111. T. Stroffolini, A. Mele, M.E. Tosti, G. Gallo, E. Balocchini, P. Ragni, F. Santonastasi, A. Marzolini, M. Ciccozzi, and A. Moiraghi The impact of the hepatitis B mass immunisation campaign on the incidence and risk factors of acute hepatitis B in Italy J. Hepatol. 33 2000 980 985
112. J. Summers, A. O'Connell, and I. Millman Genome of hepatitis B virus: restriction enzyme cleavage and structure of DNA extracted from Dane particles Proc. Natl. Acad. Sci. USA 72 1975 4597 4601
113. J.J. Sung, K.K. Tsoi, V.W. Wong, K.C. Li, and H.L. Chan Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma Aliment. Pharmacol. Ther. 28 2008 1067 1077
114. K. Takahashi, K. Aoyama, N. Ohno, K. Iwata, Y. Akahane, K. Baba, H. Yoshizawa, and S. Mishiro The precore/core promoter mutant (T1762A1764) of hepatitis B virus: clinical significance and an easy method for detection J. Gen. Virol. 76 Pt 12 1995 3159 3164
115. H. Tang, N. Oishi, S. Kaneko, and S. Murakami Molecular functions and biological roles of hepatitis B virus x protein Cancer Sci. 97 2006 977 983
116. M. Tarocchi, S. Polvani, G. Marroncini, and A. Galli Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis World J. Gastroenterol. 20 2014 11630 11640
117. The EASL Jury EASL international consensus conference on hepatitis B: 13-14 september, 2002 Geneva, Switzerland consensus statement (long version) J. Hepatol. 39 2003 3 25
118. H.T. Tzeng, H.F. Tsai, H.J. Liao, Y.J. Lin, L. Chen, P.J. Chen, and P.N. Hsu PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model PLoS ONE 7 2012 e39179
119. M. van Zonneveld, P. Honkoop, B.E. Hansen, H.G.M. Niesters, S.D. Murad, R.A. de Man, S.W. Schalm, and H.L.A. Janssen Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B Hepatology 39 2004 804 810
120. T. Vanwolleghem, J. Hou, G. van Oord, A.C. Andeweg, A.D. Osterhaus, S.D. Pas, H.L. Janssen, and A. Boonstra Re-evaluation of hepatitis B virus clinical phases by systems biology identifies unappreciated roles for the innate immune response and B cells Hepatology 2015
121. R. Walsh, and S. Locarnini Hepatitis B precore protein: pathogenic potential and therapeutic promise Yonsei Med. J. 53 2012 875 885
122. X.Y. Wang, Z.M. Wei, G.Y. Wu, J.H. Wang, Y.J. Zhang, J. Li, H.H. Zhang, X.W. Xie, X. Wang, Z.H. Wang, L. Wei, Y. Wang, and H.S. Chen In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations Antivir. Ther. 17 2012 793 803
123. N. Warner, and S. Locarnini Replication of hepatitis B virus T.D. Boyer, M.P. Manns, A.J. Sanyal, Zakim and Boyer's Hepatology: A Textbook of Liver Disease 6 ed. 2012 Elsevier Philadelphia
124. N.D. Weber, D. Stone, R.H. Sedlak, H.S. De Silva Feelixge, P. Roychoudhury, J.T. Schiffer, M. Aubert, and K.R. Jerome AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication PLoS ONE 9 2014 e97579
125. C.I. Wooddell, D.B. Rozema, M. Hossbach, M. John, H.L. Hamilton, Q. Chu, J.O. Hegge, J.J. Klein, D.H. Wakefield, C.E. Oropeza, J. Deckert, I. Roehl, K. Jahn-Hoffmann, P. Hadwiger, H.P. Vornlocher, A. McLachlan, and D.L. Lewis Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection Mol. Ther. 21 2013 973 985
126. J. Wu, Z. Meng, M. Jiang, R. Pei, M. Trippler, R. Broering, A. Bucchi, J.P. Sowa, U. Dittmer, D. Yang, M. Roggendorf, G. Gerken, M. Lu, and J.F. Schlaak Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells Hepatology 49 2009 1132 1140
127. C. Xu, G. Haitao, X.-B. Pan, R. Mao, W. Yu, X. Xu, L. Wei, J. Chang, T.M. Block, and J.-T. Guo Interferons accelerate decay of replication-competent nucleocapsid of hepatitis B virus J. Virol. 84 2010 9332 9340
128. Y.B. Xu, L. Yang, G.F. Wang, X.K. Tong, Y.J. Wang, Y. Yu, J.F. Jing, C.L. Feng, P.L. He, W. Lu, W. Tang, and J.P. Zuo Benzimidazole derivative, BM601, a novel inhibitor of hepatitis B virus and HBsAg secretion Antiviral Res. 107 2014 6 15
129. H. Yan, G. Zhong, G. Xu, W. He, Z. Jing, Z. Gao, Y. Huang, Y. Qi, B. Peng, H. Wang, L. Fu, M. Song, P. Chen, W. Gao, B. Ren, Y. Sun, T. Cai, X. Feng, J. Sui, and W. Li Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus Elife 2014 3
130. Yan, H.; Liu, Y.; Sui, J.; Li, W. 2015. NTCP opens the door for hepatitis B virus infection. Antiviral Res. [Epub ahead of print].
131. J.L. Yao Perinatal transmission of hepatitis B virus infection and vaccination in China Gut 38 1996 S37 38
132. W. Yu, C. Goddard, E. Clearfield, C. Mills, T. Xiao, H. Guo, J.D. Morrey, N.E. Motter, K. Zhao, T.M. Block, A. Cuconati, and X. Xu Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion J. Med. Chem. 54 2011 5660 5670
133. M.B. Zeisel, J. Lucifora, W.S. Mason, C. Sureau, J. Beck, M. Levrero, M. Kann, P.A. Knolle, M. Benkirane, D. Durantel, M.L. Michel, B. Autran, F.L. Cosset, H. Strick-Marchand, C. Trepo, J.H. Kao, F. Carrat, K. Lacombe, R.F. Schinazi, F. Barre-Sinoussi, J.F. Delfraissy, and F. Zoulim Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure Gut 2015
134. H. Zhuang, A.G. Coulepis, P. Zimmet, R. Taylor, P. Ram, S. Banuve, and I.D. Gust Seroepidemiology of infection with hepatitis B virus in Fiji Am. J. Epidemiol. 116 1982 608 616
135. R. Zoutendijk, B.E. Hansen, A.J. van Vuuren, C.A. Boucher, and H.L. Janssen Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss J. Infect. Dis. 204 2011 415 418